European Commission Grants Marketing Authorization for Eisai's Zonegran for epilepsy
Main Category: EpilepsyArticle Date: 21 Mar 2005 - 0:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  | |
| Healthcare Prof: | |
Tokyo (JCNN) - Eisai announced on March 16 that its UK subsidiary Eisai Ltd. has received marketing authorization for Zonegran from the European Commission (EC) as of March 10.
This authorization allows the product to be marketed in EU countries for the adjunctive treatment for partial seizures of adult epilepsy patients.
Developed by Eisai, the zonisamide agent Zonegran is currently marketed in the US and Japan (trade name Excegran). By adding the product to its line of nerve drugs, the company aims to meet patients' needs and increase its presence in the EU.
View Eisai Co., Ltd. company profile here
Copyright © 2001-2004 JCNN. All rights reserved. A division of Japan Corporate News Network KK.
Visit our epilepsy section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/21570.php>
APA
http://www.medicalnewstoday.com/releases/21570.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
